ZEALAND PHARMA A/S
Last · XETRA€37.77-0.64 (-1.67%)close · yahoo · 42h ago
Market cap€2.6B67.7M sh
P/E · TTM7.2fwd — · eps 5.24
Beta0.59vs S&P 500
Div yield—annual · TTM
52w range
€37.77€44.12
Volume31session
| Revenue | DKK 9.2B |
|---|---|
| Operating income | DKK 7.0B |
| Net income | DKK 6.5B |
| Free cash flow | DKK 6.5B |
| Operating margin | 75.5% |
| Net margin | 70.0% |
| Return on equity | 43.5% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2025-04-15
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Runway Low
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1720.9%
- Cash Runway Low — Cash runway ~0.5 years
- Rd Intensity High — R&D/Revenue 1467.3%
Upcoming earnings
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
—
Est. revenue
119.1M
Press & signals
- GlobeNewswire
Zealand Pharma – Notification of holding of treasury shares
- GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
- GlobeNewswire
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags